Cetera Advisor Networks LLC Aldeyra Therapeutics, Inc. Transaction History

Cetera Advisor Networks LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$2.77 - $4.22 $1,614 - $2,460	583 Added 3.99%	15,177 $49,000
Q4 2023 Feb 13, 2024	SELL	$1.47 - $6.06 $855 - $3,526	-582 Reduced 3.84%	14,594 $51,000
Q3 2023 Nov 14, 2023	SELL	$6.11 - $8.16 $11,444 - $15,283	-1,873 Reduced 10.99%	15,176 $101,000
Q2 2023 Aug 09, 2023	BUY	$7.11 - $11.89 $18,777 - $31,401	2,641 Added 18.33%	17,049 $143,000
Q4 2022 Feb 14, 2023	SELL	$5.08 - $7.09 $35,651 - $49,757	-7,018 Reduced 32.75%	14,408 $100,000
Q4 2021 Feb 14, 2022	BUY	$3.5 - $9.63 $74,991 - $206,332	21,426 New	21,426 $86,000
Q2 2021 Aug 13, 2021	SELL	$10.44 - $14.85 $116,802 - $166,141	-11,188 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$4.0 - $7.53 $44,752 - $84,245	11,188 New	11,188 $83,000

116

36.4M

196K

142K

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $307M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

Get notified when there are updates to the investment portfolio of Cetera Advisor Networks LLC, based on Form 13F filings with the SEC.

Stay updated on Cetera Advisor Networks LLC with notifications on news.